EHC vs. GILD: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at EHC and GILD, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | EHC | GILD |
|---|---|---|
| Company Name | Encompass Health Corporation | Gilead Sciences, Inc. |
| Country | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Health Care Providers & Services | Biotechnology |
| Market Capitalization | 12.00 billion USD | 149.07 billion USD |
| Exchange | NYSE | NasdaqGS |
| Listing Date | September 24, 1986 | January 22, 1992 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of EHC and GILD by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | EHC | GILD |
|---|---|---|
| 5-Day Price Return | 2.25% | 8.94% |
| 13-Week Price Return | 1.88% | 15.72% |
| 26-Week Price Return | 20.82% | 22.54% |
| 52-Week Price Return | 37.15% | 64.60% |
| Month-to-Date Return | 8.19% | 6.99% |
| Year-to-Date Return | 29.00% | 30.06% |
| 10-Day Avg. Volume | 1.09M | 7.34M |
| 3-Month Avg. Volume | 0.92M | 8.21M |
| 3-Month Volatility | 26.29% | 34.21% |
| Beta | 0.96 | 0.37 |
Profitability
Return on Equity (TTM)
EHC
24.70%
Health Care Providers & Services Industry
- Max
- 26.03%
- Q3
- 13.74%
- Median
- 8.26%
- Q1
- 4.13%
- Min
- -3.62%
In the upper quartile for the Health Care Providers & Services industry, EHC’s Return on Equity of 24.70% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
GILD
32.97%
Biotechnology Industry
- Max
- 77.14%
- Q3
- 10.76%
- Median
- -20.08%
- Q1
- -42.71%
- Min
- -119.20%
In the upper quartile for the Biotechnology industry, GILD’s Return on Equity of 32.97% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
Net Profit Margin (TTM)
EHC
9.22%
Health Care Providers & Services Industry
- Max
- 12.40%
- Q3
- 5.93%
- Median
- 1.96%
- Q1
- 0.93%
- Min
- -6.10%
A Net Profit Margin of 9.22% places EHC in the upper quartile for the Health Care Providers & Services industry, signifying strong profitability and more effective cost management than most of its peers.
GILD
21.87%
Biotechnology Industry
- Max
- 59.44%
- Q3
- 16.21%
- Median
- -11.49%
- Q1
- -167.42%
- Min
- -409.07%
A Net Profit Margin of 21.87% places GILD in the upper quartile for the Biotechnology industry, signifying strong profitability and more effective cost management than most of its peers.
Operating Profit Margin (TTM)
EHC
17.06%
Health Care Providers & Services Industry
- Max
- 19.05%
- Q3
- 10.21%
- Median
- 4.22%
- Q1
- 1.98%
- Min
- -4.27%
An Operating Profit Margin of 17.06% places EHC in the upper quartile for the Health Care Providers & Services industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
GILD
27.89%
Biotechnology Industry
- Max
- 60.62%
- Q3
- 20.76%
- Median
- -12.41%
- Q1
- -181.14%
- Min
- -482.02%
An Operating Profit Margin of 27.89% places GILD in the upper quartile for the Biotechnology industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
Profitability at a Glance
| Symbol | EHC | GILD |
|---|---|---|
| Return on Equity (TTM) | 24.70% | 32.97% |
| Return on Assets (TTM) | 7.91% | 11.19% |
| Net Profit Margin (TTM) | 9.22% | 21.87% |
| Operating Profit Margin (TTM) | 17.06% | 27.89% |
| Gross Profit Margin (TTM) | 95.62% | 78.53% |
Financial Strength
Current Ratio (MRQ)
EHC
1.06
Health Care Providers & Services Industry
- Max
- 2.01
- Q3
- 1.49
- Median
- 1.30
- Q1
- 0.94
- Min
- 0.17
EHC’s Current Ratio of 1.06 aligns with the median group of the Health Care Providers & Services industry, indicating that its short-term liquidity is in line with its sector peers.
GILD
1.32
Biotechnology Industry
- Max
- 19.31
- Q3
- 9.38
- Median
- 4.54
- Q1
- 2.45
- Min
- 0.76
GILD’s Current Ratio of 1.32 falls into the lower quartile for the Biotechnology industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
Debt-to-Equity Ratio (MRQ)
EHC
1.08
Health Care Providers & Services Industry
- Max
- 2.17
- Q3
- 1.18
- Median
- 0.74
- Q1
- 0.45
- Min
- 0.00
EHC’s Debt-to-Equity Ratio of 1.08 is typical for the Health Care Providers & Services industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
GILD
1.27
Biotechnology Industry
- Max
- 1.35
- Q3
- 0.64
- Median
- 0.09
- Q1
- 0.00
- Min
- 0.00
GILD’s leverage is in the upper quartile of the Biotechnology industry, with a Debt-to-Equity Ratio of 1.27. While this approach can boost equity growth, it also exposes the company to greater financial vulnerability.
Interest Coverage Ratio (TTM)
EHC
6.58
Health Care Providers & Services Industry
- Max
- 14.47
- Q3
- 7.15
- Median
- 5.45
- Q1
- 2.04
- Min
- -4.44
EHC’s Interest Coverage Ratio of 6.58 is positioned comfortably within the norm for the Health Care Providers & Services industry, indicating a standard and healthy capacity to cover its interest payments.
GILD
1.71
Biotechnology Industry
- Max
- 72.37
- Q3
- 1.91
- Median
- -7.81
- Q1
- -63.90
- Min
- -153.80
GILD’s Interest Coverage Ratio of 1.71 is positioned comfortably within the norm for the Biotechnology industry, indicating a standard and healthy capacity to cover its interest payments.
Financial Strength at a Glance
| Symbol | EHC | GILD |
|---|---|---|
| Current Ratio (MRQ) | 1.06 | 1.32 |
| Quick Ratio (MRQ) | 0.87 | 0.89 |
| Debt-to-Equity Ratio (MRQ) | 1.08 | 1.27 |
| Interest Coverage Ratio (TTM) | 6.58 | 1.71 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
EHC
0.56%
Health Care Providers & Services Industry
- Max
- 5.38%
- Q3
- 2.22%
- Median
- 0.55%
- Q1
- 0.00%
- Min
- 0.00%
EHC’s Dividend Yield of 0.56% is consistent with its peers in the Health Care Providers & Services industry, providing a dividend return that is standard for its sector.
GILD
3.97%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
GILD’s Dividend Yield of 3.97% is exceptionally high, placing it well above the typical range for the Biotechnology industry. While this may seem attractive, an unusually high yield can sometimes be a warning sign, reflecting a falling stock price or market concerns about the dividend’s sustainability.
Dividend Payout Ratio (TTM)
EHC
12.84%
Health Care Providers & Services Industry
- Max
- 186.69%
- Q3
- 74.82%
- Median
- 26.76%
- Q1
- 0.00%
- Min
- 0.00%
EHC’s Dividend Payout Ratio of 12.84% is within the typical range for the Health Care Providers & Services industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
GILD
117.08%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
At 117.08%, GILD’s Dividend Payout Ratio is exceptionally high, exceeding the typical range for the Biotechnology industry. While this provides a significant return to shareholders, it may limit funds for reinvestment and could be difficult to sustain.
Dividend at a Glance
| Symbol | EHC | GILD |
|---|---|---|
| Dividend Yield (TTM) | 0.56% | 3.97% |
| Dividend Payout Ratio (TTM) | 12.84% | 117.08% |
Valuation
Price-to-Earnings Ratio (TTM)
EHC
22.92
Health Care Providers & Services Industry
- Max
- 55.89
- Q3
- 30.85
- Median
- 21.17
- Q1
- 12.63
- Min
- 0.00
EHC’s P/E Ratio of 22.92 is within the middle range for the Health Care Providers & Services industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
GILD
23.61
Biotechnology Industry
- Max
- 60.14
- Q3
- 38.17
- Median
- 29.01
- Q1
- 15.12
- Min
- 0.00
GILD’s P/E Ratio of 23.61 is within the middle range for the Biotechnology industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
Price-to-Sales Ratio (TTM)
EHC
2.11
Health Care Providers & Services Industry
- Max
- 3.10
- Q3
- 1.74
- Median
- 0.67
- Q1
- 0.24
- Min
- 0.00
EHC’s P/S Ratio of 2.11 is in the upper echelon for the Health Care Providers & Services industry. This means the company is valued richly on its revenue stream compared to its peers, suggesting the stock is priced for a high level of future performance.
GILD
5.16
Biotechnology Industry
- Max
- 76.98
- Q3
- 36.53
- Median
- 9.49
- Q1
- 4.49
- Min
- 0.00
GILD’s P/S Ratio of 5.16 aligns with the market consensus for the Biotechnology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
Price-to-Book Ratio (MRQ)
EHC
5.43
Health Care Providers & Services Industry
- Max
- 7.61
- Q3
- 4.32
- Median
- 2.53
- Q1
- 1.14
- Min
- 0.77
EHC’s P/B Ratio of 5.43 is in the upper tier for the Health Care Providers & Services industry. This indicates that investors are paying a premium relative to the company’s net assets, a valuation that hinges on its ability to generate superior profits.
GILD
7.01
Biotechnology Industry
- Max
- 20.53
- Q3
- 9.76
- Median
- 4.77
- Q1
- 2.49
- Min
- 0.59
GILD’s P/B Ratio of 7.01 is within the conventional range for the Biotechnology industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
Valuation at a Glance
| Symbol | EHC | GILD |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 22.92 | 23.61 |
| Price-to-Sales Ratio (TTM) | 2.11 | 5.16 |
| Price-to-Book Ratio (MRQ) | 5.43 | 7.01 |
| Price-to-Free Cash Flow Ratio (TTM) | 27.28 | 16.31 |